Multiplexed, Rapid, Point of Care Device to Quantify Specific IgE to Common Aller

描述（由申请人提供）：所提出的研究的主要目标是开发一种经校准的、紧凑的、廉价的、多路复用的、具有组合的荧光和无标记能力的床旁感测平台，其适用于医学诊断领域。使用来自具有记录的过敏原特异性IgE的体外和临床证据的个体的血清作为模型系统，我们将开发一种即时护理平台，该平台将我们建立的无标记传感技术与我们的增强荧光技术校准荧光增强（CaFE）相结合。我们建议，该平台将更准确和灵敏地检测感兴趣的蛋白质的特异性抗体的存在。护理点的能力将允许有效的技术应用和加强病人护理。当前测试的局限性在于在远离护理点的临床或参考实验室中利用荧光测量，而捕获感兴趣的蛋白质（例如抗体）的探针尚未被校准并且在芯片之间变化。此外，目前可用的定量无标记传感器限于超过装置的噪声基底的灵敏度水平。这项工作将设计一个校准仪器，它采用了双重模式，以改善现有的诊断技术。虽然使用过敏诊断作为模型，但基础技术是模块化的，并且可以应用于肝病和自身免疫性疾病的免疫诊断。 公共卫生相关性（由申请人提供）：拟议研究的目标是开发一个模块化平台，以便在护理点更准确地诊断医疗状况。许多检测血液中病理性抗体的测定依赖于未知数量的“捕获”蛋白来测量这些抗体。所提出的技术将量化针对直接测量的捕获蛋白量校准的结果，所有这些都在护理点和医生访问的背景下进行。

DESCRIPTION (provided by applicant): The major goal of the proposed research is to develop a calibrated, compact, inexpensive, multiplexed, point- of-care sensing platform with combined fluorescence and label-free capabilities applicable to the field of medical diagnostics. Using sera from individuals with documented in vitro and clinical evidence of allergen- specific IgE as a model system, we will develop a point-of-care platform that combines our established label- free sensing technology with our enhanced fluorescence technology, Calibrated Fluorescence Enhancement (CaFE). We propose that this platform will more accurately and sensitively detect the presence of specific antibodies to proteins of interest. The point-of-care capability will allow efficient technology application and enhance patient care. Limitations of current tests reside in utilizing fluorescence measurements in a clinical or reference laboratory away from the point-of-care, while the probes capturing the proteins (e.g. antibodies) of interest have not been calibrated and vary from chip to chip. In addition, currently available quantitative label-free sensors are limited to sensitivity levels surpassing the noise floor of the device. This work will engineer a calibrated instrument, which incorporates dual modalities to improve upon existing diagnostic technology. While using allergy diagnostics as a model, the underlying technology is modular, and could be applied to immunodiagnostics of liver disease and autoimmune disease. PUBLIC HEALTH RELEVANCE (provided by applicant): The goal of the proposed research is to develop a modular platform to more accurately diagnose medical conditions at the point of care. Many assays which detect pathologic antibodies in the blood rely on unknown quantities of 'capture' proteins to measure these antibodies. The proposed technology will quantify results calibrated against the directly measured amount of capture protein, all at the point-of-care and in the context of a physician visit.